Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal-Reference-Cited by-同舟云学术

Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Published:2016-02-18 Issue:7 Volume:34 Page:673-680
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Squires Hazel,Stevenson Matt,Simpson Emma,Harvey Rebecca,Stevens John

Funder

National Institute for Health Research Health Technology Assessment Programme

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40273-016-0386-z.pdf

Reference20 articles.

1. National Institute for Health and Care Excellence. NICE technology appraisal guidance. 2009. Available at: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance . Accessed Dec 2015.

2. National Institute for Health and Care Excellence. Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane. 2014. Available at: https://www.nice.org.uk/guidance/ta371/ . Accessed Jan 2014.

3. European Medicines Agency. 2014. http://www.ema.europa.eu/ema/ . Accessed Feb 2014.

4. National Institute for Health and Care Excellence. Breast cancer (HER2 positive, unresectable)—trastuzumab emtansine (after trastuzumab and taxane) (ID603). Manufacturer submission. 2014. Available at: https://www.nice.org.uk/guidance/ta371/history . Accessed Dec 2013.

5. National Institute for Health and Care Excellence. Advanced breast cancer: diagnosis and treatment. NICE guidelines (CG81). 2009. Available at: https://www.nice.org.uk/guidance/cg81 . Accessed Jan 2014.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The endosomal-lysosomal system in ADC design and cancer therapy;Expert Opinion on Biological Therapy;2023-11-02

2. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience;Current Cancer Drug Targets;2023-10-24

3. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression;Clinical Breast Cancer;2023-07

4. Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis;The Breast;2022-12

5. Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis;Frontiers in Pharmacology;2022-10-28